GlobeNewswire: Veritas Pharma Inc. Contains the last 10 of 67 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T02:02:53ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/07/23/1886772/0/en/Veritas-Reaches-a-Mutual-Settlement-with-Arbutus-Biopharma-Corporation.html?f=22&fvtc=4&fvtv=40682Veritas Reaches a Mutual Settlement with Arbutus Biopharma Corporation2019-07-23T21:00:00Z<![CDATA[VANCOUVER, British Columbia, July 23, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Puerto Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas”), is pleased to announce that it has reached a settlement with Arbutus Biopharma Corporation (“Arbutus”) with respect to the litigation commenced by Arbutus. The claims relate to a commercial lease space, which Veritas no longer believes is necessary for its R&D.]]>https://www.globenewswire.com/news-release/2019/07/10/1881149/0/en/Veritas-Announces-the-Sale-of-3-Carbon-Extractions-Inc.html?f=22&fvtc=4&fvtv=40682Veritas Announces the Sale of 3 Carbon Extractions Inc.2019-07-10T21:00:00Z<![CDATA[VANCOUVER, British Columbia, July 10, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces that it has completed the sale of its interest in 3 Carbon Extractions Inc. (“3 Carbon”) to Mr. Yari Nieken for cash consideration of $375,000.]]>https://www.globenewswire.com/news-release/2019/05/15/1825699/0/en/Veritas-Announces-Restructuring-of-Cannevert-Therapeutics-Ltd.html?f=22&fvtc=4&fvtv=40682Veritas Announces Restructuring of Cannevert Therapeutics Ltd.2019-05-15T21:30:00Z<![CDATA[VANCOUVER, British Columbia, May 15, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces that it has undertaken steps to restructure and rebuild Cannevert Therapeutics Ltd. (“CTL”), a wholly owned subsidiary of Veritas.]]>https://www.globenewswire.com/news-release/2019/05/15/1825164/0/en/Veritas-Announces-the-Completion-of-Clinical-Trial-on-their-Cannabis-Product-for-Treatment-of-Acute-Pain.html?f=22&fvtc=4&fvtv=40682Veritas Announces the Completion of Clinical Trial on their Cannabis Product for Treatment of Acute Pain2019-05-15T12:00:00Z<![CDATA[SAN JUAN, Puerto Rico, May 15, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Puerto Rico, Inc., a wholly owned subsidiary of Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas”), is pleased to announce the completion of its clinical trial on its lead cannabis treatment (“CTL-X”) for acute pain. The clinical trial was designed as a randomized, double-blinded, cross-over trial and tested the efficacy of vaporized CTL-X for the treatment of acute pain in healthy adult subjects.]]>https://www.globenewswire.com/news-release/2019/03/27/1773903/0/en/Veritas-Pharma-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=40682Veritas Pharma Provides Corporate Update2019-03-27T12:00:00Z<![CDATA[VANCOUVER, British Columbia, March 27, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce corporate highlights and to communicate the company’s direction for the year ahead.]]>https://www.globenewswire.com/news-release/2019/03/04/1747512/0/en/UPDATE-Veritas-Pharma-to-Commence-Legal-Proceedings-Against-Liht-Cannabis.html?f=22&fvtc=4&fvtv=40682UPDATE -- Veritas Pharma to Commence Legal Proceedings Against Liht Cannabis2019-03-04T19:10:00Z<![CDATA[VANCOUVER, British Columbia, March 04, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces that it has filed a claim and is commencing legal proceedings against Liht Cannabis Corp. ("Liht") (formerly Marapharm Ventures Inc.) to recover a loan made by Veritas to Liht in the amount of $1,000,000.00 plus accrued interest. The loan is in default and Veritas has made demand for repayment but Liht has refused to make repayment.]]>https://www.globenewswire.com/news-release/2019/03/04/1746353/0/en/Veritas-Pharma-to-Commence-Legal-Proceedings-Against-Liht-Cannabis.html?f=22&fvtc=4&fvtv=40682Veritas Pharma to Commence Legal Proceedings Against Liht Cannabis2019-03-04T18:32:50Z<![CDATA[VANCOUVER, British Columbia, March 04, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces that it has filed a claim and is commencing legal proceedings against Liht Cannabis Corp. ("Liht") (formerly Marapharm Ventures Inc.) to recover a loan made by Veritas to Liht in the amount of $1,000,000.00 plus accrued interest. The loan is in default and Veritas has made demand for repayment but Liht has refused to make repayment.]]>https://www.globenewswire.com/news-release/2019/02/22/1740350/0/en/Veritas-Enrolls-First-Patient-in-Clinical-Study-to-Assess-Pain-Control-with-Lead-Product.html?f=22&fvtc=4&fvtv=40682Veritas Enrolls First Patient in Clinical Study to Assess Pain Control with Lead Product2019-02-22T14:43:59Z<![CDATA[SAN JUAN, Puerto Rico, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Puerto Rico LLC, a wholly owned subsidiary of Veritas Pharma, Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas”), today announced the dosing of the first adult volunteer in its clinical trial of their lead cannabis product (“CTL-X”) for the treatment of acute pain. The randomized, double-blinded crossover trial will assess the safety, tolerability and efficacy of CTL-X as a single dose vaporized challenge in 16 healthy adults. CTL-X, supplied by one of Puerto Rico’s notable cannabis performers, the Institute for Medical Cannabis (“IMC”), will be evaluated on its analgesic properties on simulated pain using standardized pain scales. The clinical research organization, Fundación de Investigación (“FDI”), administered the trial drug in the phase II-III unit at their state-of-the-art facility. Veritas and FDI anticipate data from the clinical trial in May 2019.]]>https://www.globenewswire.com/news-release/2019/02/12/1720860/0/en/Veritas-Pharma-Enters-into-agreement-to-acquire-Commercial-Hemp-and-Cannabis-Processing-Facility.html?f=22&fvtc=4&fvtv=40682Veritas Pharma Enters into agreement to acquire Commercial Hemp and Cannabis Processing Facility2019-02-12T14:00:00Z<![CDATA[VANCOUVER, British Columbia, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that it has entered into an agreement with TG Initiatives Ltd., to purchase a commercial processing facility for hemp and cannabis products(“asset”), that asset is capable of making a variety of hemp and cannabis products including edibles for human and animal use. Additionally, this asset provides the capability to make a variety of natural topical creams for pain relief and other ailments including any product that come out of the company’s acute pain reduction human trials recently announced in Puerto Rico.]]>https://www.globenewswire.com/news-release/2019/02/11/1720452/0/en/Veritas-Pharma-Announces-the-Resignation-of-CEO-Dr-Lui-Franciosi.html?f=22&fvtc=4&fvtv=40682Veritas Pharma Announces the Resignation of CEO, Dr. Lui Franciosi2019-02-11T23:14:16Z<![CDATA[VANCOUVER, British Columbia, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces the resignation of its President, CEO and Director, Dr. Lui Franciosi. Company Interim CFO, Mr. Peter McFadden will fill the executive roles in the interim until a qualified replacement is found.]]>